Cartesian Therapeutics, Inc.
RNAC
$10.79
-$0.46-4.09%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Revenue | 1.03M | 34.17M | 38.91M | 47.94M | 54.10M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 1.03M | 34.17M | 38.91M | 47.94M | 54.10M |
| Cost of Revenue | 25.79M | 24.76M | 24.19M | 29.14M | 30.74M |
| Gross Profit | -24.77M | 9.42M | 14.72M | 18.80M | 23.36M |
| SG&A Expenses | 29.20M | 28.99M | 29.53M | 38.78M | 38.83M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 81.45M | 79.03M | 74.43M | 88.63M | 90.28M |
| Operating Income | -80.43M | -44.86M | -35.52M | -40.69M | -36.18M |
| Income Before Tax | -35.97M | -38.02M | -77.14M | -263.83M | -248.65M |
| Income Tax Expenses | 287.00K | 287.00K | 287.00K | -19.00M | -19.00M |
| Earnings from Continuing Operations | -36.26 | -38.31 | -77.42 | -244.83 | -229.65 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -36.26M | -38.31M | -77.42M | -244.83M | -229.65M |
| EBIT | -80.43M | -44.86M | -35.52M | -40.69M | -36.18M |
| EBITDA | -77.91M | -42.74M | -34.37M | -39.75M | -35.34M |
| EPS Basic | -1.60 | -1.54 | -10.67 | -50.92 | -51.54 |
| Normalized Basic EPS | -1.59 | -0.70 | -2.20 | -21.41 | -22.24 |
| EPS Diluted | -1.62 | -1.58 | -10.72 | -50.96 | -51.58 |
| Normalized Diluted EPS | -1.59 | -0.73 | -2.22 | -21.43 | -22.26 |
| Average Basic Shares Outstanding | 98.78M | 89.52M | 69.03M | 48.90M | 32.59M |
| Average Diluted Shares Outstanding | 99.24M | 90.59M | 70.10M | 49.97M | 33.66M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |